
Curriculum Vitae

ARUN CHERVU, M.D., MBA, MHA, FACS, RVT
AIC Medical Consultants, LLC
Email: achervu@aicmedicalconsultants.com
Cell: 770-370-7175



Executive Summary

I am an Ivy-league educated vascular surgeon with over 30 years of experience in clinical practice, trained at premier residency and fellowship programs. My expertise includes wound care, lower extremity ulcers, dialysis access, deep vein thrombosis, amputations, peripheral vascular procedures, and venous insufficiency. I am recognized for my work in teaching, peer review, quality and safety initiatives, and clinical research. I have extensive leadership experience in clinical program expansion, medical staff governance, and multi-disciplinary committee service, I have served as President of the Georgia Vascular Society and the Georgia Vascular Foundation. I deliver expert, evidence-based insights and solutions to support medico-legal analysis.

Education & Training

- **Georgia State University, GA, PMBA/MHA, 2012-2014**
- **UCLA School of Medicine, CA, Fellowship, Vascular Surgery, 1991-1992**
- **UCLA School of Medicine, CA, Residency, General Surgery, 1984–1991**
- **Cornell University Medical College, NY, M.D., 1980–1984**
- **Princeton University, NJ, B.S.E., Chemical Engineering, Magna Cum Laude, 1976–1980**

Academic Appointments

- **Clinical Faculty, Medical College of Georgia at Augusta University (2013-Present)**
 - **Faculty, Kennestone Regional Medical Center, General Surgery Residency Program (2022 – Present)**
 - **Assistant Professor of Surgery, University of Texas, Southwestern Medical Center & Dallas VAMC, Dallas, Texas (1992-1995)**
-

Professional & Leadership Experience

Hyperbaric Physicians of Georgia, Marietta, GA (from 3/1/2026)

- Evaluate and treat chronic, non-healing wounds
- Evaluate & coordinate treatment plans for patients referred for hyperbaric oxygen therapy (HBOT):
 - Certain chronic, non-healing wounds
 - Select radiation-related tissue injuries
 - Some compromised skin grafts and flaps
 - Specific infections where high oxygen levels may support healing

Vascular Surgical Associates, P.C. (VSA) Marietta, GA (1995-2025)

- **Clinical Expertise with over 1000 cases/year:**
 - Lower Extremity Wounds & Wound Care
 - Medical and Endovascular Treatment of Deep Venous Thrombosis (DVT)
 - Dialysis Access Creation & Maintenance
 - Central Line Placement & Removal
 - Quality & Safety
 - Outpatient Based Labs (OBL)
 - Venous Insufficiency Evaluation & Treatment
 - Amputation & Prosthetics
 - Vascular Ultrasound
 - Endovascular & Open Peripheral Vascular Procedures
 - Management of Carotid Disease (including carotid stenting - TCAR)
- Led and advanced key VSA initiatives:
 - Expanded practice from 2 to 11 offices, increasing patient access and market share.
 - VSA Board Member since 2001, contributing to strategic planning, financial oversight, and operational leadership.
 - VSA Vice President, Secretary and Treasurer, VSA, 2001–2025.
 - Co-director, VSA Prosthetics; Medical Director, Vascular Quality Initiative (VQI).
 - Director of Clinical Studies, overseeing physician schedules, and extender training.
- Developed and taught multiple courses for Physicians and APPs on Ultrasound Guided Central Venous Access with Didactic & Hands-on Training
- Preceptor for high school and college students interested in medical careers.

Wellstar Health System (1995–2025)

- Board Member & Wellstar Cobb Hospital Chair, Wellstar Clinical Partners
- Chief of Surgery, WellStar Cobb Hospital (2023–2024)
- Chief of Medical Staff, Wellstar Cobb Hospital (2007–2008)
- Credentials Committee & Surgical Staff Leadership (20+ years), Wellstar Cobb Hospital
- Led strategy for vascular service line development across Wellstar Health System

- Extensive leadership on Surgery and Multidisciplinary Peer Review Committees

UT Southwestern & Dallas VA Medical Center – Dallas, TX (1992–1995)

Assistant Professor of Vascular Surgery

- Delivered patient care, supervised trainees, and conducted clinical/basic science research.
- Co-Director of STAMP Program, Dallas VAMC

Licenses & Certifications

- Georgia Composite State Board of Medical Examiners - Valid till November 2027
- Medical Board of California - Valid till October 2026
- Drug Enforcement Administration - Valid till August 2028
- American Board of Surgery Added Qualifications in General Vascular Surgery – Certified till December 2026
- American Board of Surgery, General Surgery, not renewed after December 2024.
- Fellow, American College of Surgeons (1995 to Present)
- The American Registry of Diagnostic Medical Sonographers, Registered Vascular Technologist, Valid till December 2026.

Hospital Appointments (Active & Past)

- WellStar Kennestone Regional Medical Center, Marietta, GA (1995–2025)
- WellStar Cobb Hospital, Austell, GA, (1995–2025)
- Piedmont Cartersville Medical Center, Cartersville, GA, (2023–2025)
- Northside Cherokee Hospital, Canton, GA, (2022-2025)
- Wellstar Douglas Hospital, Douglasville, GA, (2022-2025)
- Wellstar North Fulton Hospital, Roswell, GA, (2021-2025)
- Children’s Hospital of Atlanta, Atlanta, GA, (2024-2025)
- Attending Physician, Parkland Memorial Hospital, Dallas, TX, (1992-1995)
- Attending Physician, Zale-Lipshy University Hospital, Dallas, TX, (1992-1995)
- Dallas Veterans Administration Medical Center, Dallas, TX, (1992-1995)

Professional Societies

- Society for Vascular Surgery (1995-Present)
- The Southern Association for Vascular Surgery (2000-Present)

-
- Georgia Vascular Society (Founding Member, 2013–Present; President 2022–2023)
 - Atlanta Vascular Society (1998–2013), Merged into Georgia Vascular Society.
 - American College of Healthcare Executives (2014–2018)
 - American Association for Physician Leadership (2014–2018)
-

Committees & Boards

- Georgia State University, IHA Advisory Board (2026 – Present)
 - Scientific Advisory Board (AI Startup), Vironix (2022–Present)
 - Georgia Vascular Society: President (2022–2023), Board Member (2017–Present)
 - Georgia Vascular Foundation: President (2019–2023), Board Member (2017–2023)
 - Wellstar Clinical Partners: Executive Committee (2020–2025); Chair, Wellstar Cobb Hospital (2018–2025)
 - President, Medical Staff, Wellstar Cobb Hospital (2007–2008)
 - Medical Executive Committee, Wellstar Cobb Hospital (2004–2009; 2023–2024)
 - Credentials Committee, Wellstar Cobb Hospital (2001–2024); Chair (2004–2006)
 - Wellstar Cobb Hospital: Surgical Committee to the OR & Peer Review Committees (2003–2025), Ethics Committee Chair (2011–2013)
 - Peer Review Committee, Wellstar Kennestone Hospital (2023–2024)
 - Advisory Boards: Wellstar Institute for Better Health (2006–2008); Cardiomems (2006–2008); Medtronic (2006–2008)
 - Ischemia Related Organ Dysfunction Committee, The Association of Program Directors in General Vascular Surgery (1994–1995)
 - Human Studies Subcommittee, Dallas VA Medical Center (1994–1995)
-

Honors & Awards

- President, Georgia Vascular Society, (2022–2023)
 - Atlanta Magazine “Top Doctors” (2016–2025)
 - Max G. Holland Memorial Scholarship, Highest GPA, Georgia State University (2014)
 - Safety & Quality Awards, Wellstar Health System (2008–2011, 2018)
 - Physician Partner in Excellence Award, Wellstar Cobb Hospital, 2008
 - Who’s Who Top 100 People Who Lead Atlanta’s Health-Care Industry, Atlanta Business Chronicle, 2008
 - Winner, First Annual West Coast Vascular Fellows Forum, 1992
 - Outstanding Award, Vascular Surgery Research Lab, Sepulveda VA Medical Center, 1988
 - Outstanding Resident II, Department of Surgery, 1986
 - Cardiothoracic Junior Resident of the Year, Department of Surgery, 1986
 - Magna cum Laude, Princeton University, 1980
-

-
- Tau Beta Pi, Engineering Honor Society, 1980
-

Conference & Course Organization

- Co-Chairman, Annual Wellstar Wound Conference (2002–2008)
 - Organized CME-accredited conferences on diabetic foot care, wound management, and vascular assessment
-

Prior Grant Support

1. Sigma-Tau Pharmaceuticals Inc., “Safety and Efficacy of Propionyl-L-Carnitine in Peripheral Arterial Disease (Intermittent Claudication). A Multi-Center Dose-Ranging Study.” \$150,000.
 2. New York Institute for Vascular Studies, “Rapid Endothelialization of Vascular Prostheses.” \$8,500.
 3. EndoVascular Technologies, Inc., “A Clinical Trial of the EndoVascular Grafting System (EGS) as Compared to the Standard Surgical Procedure in the Treatment of Abdominal Aortic Aneurysms (AAA),” Co-Principal Investigator, \$100,000.
 4. Intervascular, Inc., “Differential Healing of Autogenous versus Prosthetic Stented Grafts”, Principal Investigator, \$7,000.
-

Clinical Trials

1. Site Principal Investigator: GORE GRT 10-11: Global Registry for Endovascular Aortic Treatment (GREAT), 2020–2025.
 2. Site Sub-Investigator: Assessment of the GORE® EXCLUDER Conformable AAA Endoprosthesis (CEXC Device) in the Treatment of Abdominal Aortic Aneurysms (AAA 13-03), 4/2018-7/2020.
 3. Site Principal Investigator: GORE PCE 09-02: Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries, 2012–2019.
 4. Site Principal Investigator: Nycomed TC-2402-039-SP: A randomized, open label, parallel-group, multi-center trial to compare efficacy and safety of TachoSil versus Surgicel Original for the secondary hemostatic treatment of needle hole bleeding in vascular surgery, 2011–2013.
 5. Site Sub-Investigator: AtheroMed TP 0782: Endovascular Atherectomy Safety and Effectiveness (EASE) Study: A Prospective, Multicenter Clinical Evaluation of the Safety and Effectiveness of the Phoenix Atherectomy™ System in Atherectomy of the Peripheral Vasculature, 12/2010–12/2011.
-

6. Site Principal Investigator: Merck MK-0000: A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA) (MCAT), 3/09–4/2010.
7. Site Principal Investigator: Boston Scientific CDM00025278: A Boston Scientific Trial of the EPIC™ Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries (ORION), 3/09– 2014.
8. Site Principal Investigator: Boston Scientific CDM00002892: A Carotid Stenting Boston Scientific Surveillance Program, Carotid WALLSTENT® Monorail® Endoprosthesis FilterWire EZ™ Embolic Protection System (CABANA), 2/09–1/11.
9. Site Principal Investigator: Cordis P05-6201: S.M.A.R.T.™ Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease (STROLL), 11/08–2013.
10. Site Principal Investigator: A Phase III, Randomised, Double-Blind, Parallel-Group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, following Initial Treatment (5-10 days) with a Parenteral Anticoagulant Approved for this Indication. RE-COVER II, Boehringer Ingelheim BV, 9/08–4/10.
11. Site Principal Investigator: Sanofi-aventis EFC6145: A Randomized Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of 4 Administrations of XRP0038/NV1FGF 4mg at 2-week Intervals on Amputation or any Death in Critical Limb Ischemia Patients with Skin Lesions (TAMARIS), 7/08–2/11.
12. Site Principal Investigator: Gore VPR 07-03: Gore Viabahn® Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease (VIPER), 6/08–2013.
13. Site Principal Investigator: CardioMEMS CM-06-02b: Pressure and imaging using the CardioMEMS EndoSure Sensor for long-term follow-up after EVAR with standard surveillance (Prospective Registry) (PRICELESS), 6/2008–2013.
14. Site Principal Investigator: Medtronic Vascular 089: Endurant Stent Graft System US Clinical Study, 5/08-2013.
15. Site Principal Investigator: Bristol-Myers Squibb/Pfizer CV185057: A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism (AMPLIFY EXT), 4/08–2014.
16. Site Principal Investigator: Bristol-Myers Squibb/Pfizer CV185056: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism (AMPLIFY), 4/08–3/10.
17. Site Principal Investigator: RNA Expression Profiling of Lesions from in vivo Carotid Atherectomies (REPLICA): A Carotid Plaque Observational Study, eV3/Merck, 2/08–12/08.
18. Site Principal Investigator: SAPPHIRE WW, Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy, Cordis Endovascular, 8/06–2011.
19. Site Principal Investigator: Abbott Medical Devices, CHOICE: Carotid Stenting for High Surgical-Risk Patients, 2006-2012.
20. Site Principal Investigator: A Phase III, Randomised, Double-Blind, Parallel-Group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg bid) Compared to Warfarin (INR 2.0-3.0)

for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, following Initial Treatment (5-10 days) with a Parenteral Anticoagulant Approved for this Indication. RE-COVER II, Boehringer Ingelheim BV, 9/08–4/10.

21. Site Principal Investigator: A Two-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Simvastatin, Losartan, and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Arterial Disease (LEAP), Foxhollow Technologies, Inc., 5/06–7/07.
22. Site Sub-Investigator: A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems – CAPTURE 2, Guidant Corp., 5/06–2011.
23. Site Principal Investigator: Gore Viabahn Endoprosthesis versus Bare Nitinol Stent in the Treatment of Long Lesions (>8 cm) Superficial Femoral Artery Occlusive Disease (VIBRANT), W.L. Gore Corp., 4/06–2011.
24. Site Principal Investigator: Carotid Artery Stenting with Emboli Protection Surveillance – Post-Marketing Study, CASES-PMS, Cordis Endovascular, 2/06–12/09.
25. Site Principal Investigator: The PIVOTAL STUDY- Positive Impact of Endovascular Options for Treating Aneurysms Early, Medtronic Corp., 12/05–11/09.
26. Site Principal Investigator: APEX Study - Acute Pressure Measurement to Confirm Aneurysm Sac Exclusion, Cardiometrics Inc., 11/04–11/05.
27. Site Co-Principal Investigator: A Clinical Trial of Endovascular Grafting System (EGS) as Compared to the Standard Surgical Procedure in the Treatment of Abdominal Aortic Aneurysms (AAA), Endovascular Technologies, Inc., 3/93-6/95, University of Texas Southwestern Medical Center.
28. Site Co-Principal Investigator: Safety & Efficacy of Propionyl-L-Carnitine in Peripheral Arterial Disease (Intermittent Claudication), A Multicenter Dose-Ranging Study, Sigma-Tau Pharmaceuticals, 6/93-6/95, University of Texas Southwestern Medical Center.

Scientific Articles

1. Pride, L. B., Lagergren, E. R., Hafner, D. H., & **Chervu, A. A.** (2020). Critical carotid artery stenosis involving a persistent primitive hypoglossal artery. *Journal of vascular surgery cases and innovative techniques*, 6(2), 177–180. <https://doi.org/10.1016/j.jvscit.2020.01.016>.
2. Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., Weitz, J. I., & **AMPLIFY-EXT Investigators** (2013). Apixaban for extended treatment of venous thromboembolism. *The New England journal of medicine*, 368(8), 699–708. <https://doi.org/10.1056/NEJMoa1207541>.
3. Geraghty, P. J., Mewissen, M. W., Jaff, M. R., Ansel, G. M., & **VIBRANT Investigators** (2013). Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. *Journal of vascular surgery*, 58(2), 386–95.e4. <https://doi.org/10.1016/j.jvs.2013.01.050>.

4. Saxon, R. R., **Chervu, A.**, Jones, P. A., Bajwa, T. K., Gable, D. R., Soukas, P. A., Begg, R. J., Adams, J. G., Ansel, G. M., Schneider, D. B., Eichler, C. M., & Rush, M. J. (2013). Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. *Journal of vascular and interventional radiology : JVIR*, 24(2), 165–174. <https://doi.org/10.1016/j.jvir.2012.10.004> .
5. White, C. J., Avula, S. B., Mintz, R. T., Iskander, A., **Chervu, A.**, Feldman, R. L., Schermerhorn, M. L., Woo, H. H., & Hopkins, L. N. (2012). Carotid artery revascularization with distal protection in high-surgical-risk patients in routine clinical practice: rationale and design of the CABANA safety surveillance program. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*, 79(1), 167–173. <https://doi.org/10.1002/ccd.23257>.
6. Schreiber, T. L., Strickman, N., Davis, T., Kumar, V., Mishkel, G., Foster, M., Donohoe, D., Britto, S., Ansel, G., & **CASES-PMS Investigators** (2010). Carotid artery stenting with emboli protection surveillance study: outcomes at 1 year. *Journal of the American College of Cardiology*, 56(1), 49–57. <https://doi.org/10.1016/j.jacc.2010.02.045> .
7. Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., Goldhaber, S. Z., & RE-COVER Study Group (2009). Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *The New England journal of medicine*, 361(24), 2342–2352. <https://doi.org/10.1056/NEJMoa0906598>.
8. Katzen, B. T., Criado, F. J., Ramee, S. R., Massop, D. W., Hopkins, L. N., Donohoe, D., Cohen, S. A., Mauri, L., & **CASES-PMS Investigators** (2007). Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study. *Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions*, 70(2), 316–323. <https://doi.org/10.1002/ccd.21222> .
9. Hansen, M. E., Valentine, R. J., McIntire, D. D., Myers, S. I., **Chervu, A.**, & Clagett, G. P. (1995). Age-related differences in the distribution of peripheral atherosclerosis: when is atherosclerosis truly premature?. *Surgery*, 118(5), 834–839. [https://doi.org/10.1016/s0039-6060\(05\)80273-9](https://doi.org/10.1016/s0039-6060(05)80273-9) .
10. Myers, S. I., Clagett, G. P., Valentine, R. J., Hansen, M. E., Anand, A., & **Chervu, A.** (1996). Chronic intestinal ischemia caused by intravenous cocaine use: report of two cases and review of the literature. *Journal of vascular surgery*, 23(4), 724–729. [https://doi.org/10.1016/s0741-5214\(96\)80057-7](https://doi.org/10.1016/s0741-5214(96)80057-7) .
11. Maier, J. S., Barbieri, B., **Chervu, A.**, Chervu, I., Rantini, S., Franceshni, M. A., Levi, M., Martulin, W. W., Rosenberg, A., Walker, S. A., & Gratton, E. (1995). In vivo study of human tissues with a portable near-infrared tissue spectrophotometer. In *Advances in Laser and Light Spectroscopy to Diagnose Cancer and Other Diseases II* (Vol. 2387, pp. 240-248). SPIE.
12. **Chervu, A.**, Clagett, G. P., Valentine, R. J., Myers, S. I., & Rossi, P. J. (1995). Role of physical examination in detection of abdominal aortic aneurysms. *Surgery*, 117(4), 454–457. [https://doi.org/10.1016/s0039-6060\(05\)80067-4](https://doi.org/10.1016/s0039-6060(05)80067-4) .
13. **Chervu, A.** (1995). Chervu A. (1995). Recurrent carotid artery stenosis: diagnosis, management, and prevention. *Seminars in vascular surgery*, 8(1), 70–76.

14. Valentine, R. J., Hansen, M. E., Myers, S. I., **Chervu, A.**, & Clagett, G. P. (1995). The influence of sex and aortic size on late patency after aortofemoral revascularization in young adults. *Journal of vascular surgery*, 21(2), 296–306. [https://doi.org/10.1016/s0741-5214\(95\)70270-9](https://doi.org/10.1016/s0741-5214(95)70270-9) .
15. Clagett, G. P., Valentine, R. J., Myers, S. I., Chervu, A., & Heller, J. (1995). Does desmopressin improve hemostasis and reduce blood loss from aortic surgery? A randomized, double-blind study. *Journal of vascular surgery*, 22(3), 223–230. [https://doi.org/10.1016/s0741-5214\(95\)70134-6](https://doi.org/10.1016/s0741-5214(95)70134-6)
16. Rossi, P. J., Valentine, R. J., Myers, S. I., Brilliant, P. T., **Chervu, A.**, & Clagett, G. P. (1995). The durability of bilateral carotid endarterectomy. *Annals of vascular surgery*, 9(1), 16–20. <https://doi.org/10.1007/BF02015312> .
17. **Chervu, A.** (1994). Book review: “Surgical Infections: Diagnosis and Treatment”, Jonathan L. Meakins. *Journal of Vascular Surgery*, 20, 491.
18. Fayiga, Y. J., Valentine, R. J., Myers, S. I., **Chervu, A.**, Rossi, P. J., & Clagett, G. P. (1994). Blunt pediatric vascular trauma: analysis of forty-one consecutive patients undergoing operative intervention. *Journal of vascular surgery*, 20(3), 419–425. [https://doi.org/10.1016/0741-5214\(94\)90141-4](https://doi.org/10.1016/0741-5214(94)90141-4) .
19. **Chervu, A.**, & Moore, W. S. (1994). Carotid endarterectomy without arteriography. *Annals of vascular surgery*, 8(3), 296–302. <https://doi.org/10.1007/BF02018179> .
20. Myers, S. I., Valentine, R. J., **Chervu, A.**, Bowers, B. L., & Clagett, G. P. (1994). Saphenous vein patch versus primary closure for carotid endarterectomy: long-term assessment of a randomized prospective study. *Journal of vascular surgery*, 19(1), 15–22. [https://doi.org/10.1016/s0741-5214\(94\)70116-4](https://doi.org/10.1016/s0741-5214(94)70116-4) .
21. Bowes, B. L., Valentine, R. J., Myers, S. I., **Chervu, A.**, & Clagett, G. P. (1993). The natural history of patients with claudication with toe pressures of 40 mm Hg or less. *Journal of vascular surgery*, 18(3), 506-511.
22. Clagett, G. P., Bowers, B. L., Lopez-Viego, M. A., Rossi, M. B., Valentine, R. J., Myers, S. I., & **Chervu, A.** (1993). Creation of a neo-aortoiliac system from lower extremity deep and superficial veins. *Annals of surgery*, 218(3), 239–249. <https://doi.org/10.1097/0000658-199309000-00003> .
23. Valentine, R. J., Clagett, G. P., Miller, G. L., Myers, S. I., Martin, J. D., & **Chervu, A.** (1993). The coronary risk of unsuspected renal artery stenosis. *Journal of vascular surgery*, 18(3), 433-440.
24. **Chervu, A.**, Ahn, S. S., McNamara, T. O., & Dorsey, D. (1993). Endovascular obliteration of in situ saphenous vein arteriovenous fistulas during tibial bypass. *Annals of vascular surgery*, 7(4), 320–324. <https://doi.org/10.1007/BF02002882> .
25. **Chervu, A.**, & Clagett, G. P. (1992). Commentary on “Influence of coronary heart disease on morbidity and mortality after carotid endarterectomy; A population-based study in Olmsted County, Minnesota (1970-1988)”. *Vascular Surgery Outlook*, 4(10).
26. **Chervu, A.**, Chervu, A., Moore, W. S., Gelabert, H. A., Colburn, M. D., & Chvapil, M. (1991). Prevention of graft infection by use of prostheses bonded with a rifampin/collagen release system. *Journal of vascular surgery*, 14(4), 521–525.
27. Quiñones-Baldrich, W. J., **Chervu, A.**, Hernandez, J. J., Colburn, M., & Moore, W. S. (1991). Skeletal muscle function after ischemia: "no reflow" versus reperfusion injury. *The Journal of surgical research*, 51(1), 5–12. [https://doi.org/10.1016/0022-4804\(91\)90062-q](https://doi.org/10.1016/0022-4804(91)90062-q) .

28. **Chervu, A.**, Moore, W. S., Chvapil, M., & Henderson, T. (1991). Efficacy and duration of antistaphylococcal activity comparing three antibiotics bonded to Dacron vascular grafts with a collagen release system. *Journal of vascular surgery*, 13(6), 897–901. <https://doi.org/10.1067/mva.1991.27349> .
 29. **Chervu, A.**, & Moore, W. S. (1990). An overview of intimal hyperplasia. *Surgery, gynecology & obstetrics*, 171(5), 433–447.
 30. **Chervu, A.**, Moore, W. S., Quiñones-Baldrich, W. J., & Henderson, T. (1989). Efficacy of corticosteroids in suppression of intimal hyperplasia. *Journal of vascular surgery*, 10(2), 129–134. <https://doi.org/10.1067/mva.1989.0100129> .
 31. **Chervu, A.**, Moore, W. S., Homsher, E., & Quinones-Baldrich, W. J. (1989). Differential recovery of skeletal muscle and peripheral nerve function after ischemia and reperfusion. *The Journal of surgical research*, 47(1), 12–19. [https://doi.org/10.1016/0022-4804\(89\)90041-3](https://doi.org/10.1016/0022-4804(89)90041-3) .
 32. **Chervu, A.**, & Quinones-Baldrich, W. J. (1988). Vascular complications in orthopedic surgery. *Clinical orthopaedics and related research*, (235), 275–288.
 33. Silberman, A. W., Rosenkranz, E., Kosakowski, C., **Chervu, A.**, Sugawara, R. I., & Ramming, K. P. (1987). A complication of the Infusaid pump: duodenal atony reversed by urecholine. *Journal of surgical oncology*, 36(3), 210–214. <https://doi.org/10.1002/jso.2930360312> .
-

Book Chapters

1. **Chervu, A.**, & Clagett, G. P. (1995). Bleeding and clotting disorders. In R. H. Dean, J. S. T. Yao, & D. C. Brewster (Eds.), *Current diagnoses and treatment in vascular surgery* (pp. 55-79). Appleton & Lange.
 2. **Chervu, A.**, & Bennion, R. (1994). Percutaneous vascular access. In D. E. Strandness & A. Breda (Eds.), *Vascular disease: Surgical and interventional therapy* (pp. 1063-1076). Churchill Livingstone.
 3. **Chervu, A.** (1993). The role of anti-platelet agents in the control of intimal hyperplasia. In W. J. Quinones-Baldrich (Ed.), *Intimal hyperplasia* (pp. 22-32). R.G. Landes Co.
 4. **Chervu, A.**, Ahn, S. A., & Moore, W. S. (1992). Current therapy of intimal hyperplasia. In W. S. Moore & S. S. Ahn (Eds.), *Endovascular surgery* (pp. 571-581). W.B. Saunders.
 5. **Chervu, A.**, & Moore, W. S. (1992). Vascular grafts and sutures. In P. R. F. Bell, C. W. Jamieson, & C. V. Ruckley (Eds.), *Surgical management of vascular diseases* (pp. 367-389). W.B. Saunders.
-

Posters & Presentations

1. L. Coffinet MD, PGY2, C. Angeletti MD, A. Chervu MD. Angiosarcoma in AVF Bed After Renal Transplant: Case Studies & Literature Review, (Case Report Presentation by Dr. Coffinet), 13th Annual Georgia Vascular Society Meeting, September 2025.
2. J. Paul MD, PGY3, A. Chervu MD, M. Corey MD, R. Gupta MD. Transcarotid Artery Revascularization (TCAR) for Neurointerventional Access Case Series, (Poster by Dr. Paul), 13th Annual Georgia Vascular Society Meeting, September 2025.
3. “PVD, Wounds, Amputation”, Palliative Care Fellows Conference, Wellstar Kennestone, February 2024.
4. Georgia Vascular Society Presidential Address: “Challenges of Current Day Vascular Practice”, September 2023.
5. “Evaluation & Management of Lower & Upper Extremity DVT”, Internal Medicine Grand Rounds, February 2023.
6. “The Diagnosis and Treatment of Peripheral Vascular Disease”, Wellstar Cobb, February 2022.
7. “Vascular Surgery – Carotid Intervention”. Wellstar Kennestone, August 2021.
8. “Vascular Surgery for Internists: Part 1”, Internal Medicine Grand Rounds, Wellstar Kennestone, August 2021.
9. “Vascular Update: 2018”, Wellstar Cobb, March 2018.
10. “Acute Aortic Infection with Clostridium Septicum,” Georgia Vascular Society, September 2014.
11. “PCP Update: Vascular Disease”, Wellstar Cobb, September 2011.
12. “Venous Thromboembolism (VTE): Prophylaxis & Treatment”, Grand Rounds, Wellstar Kennestone, February 2009.
13. “Venous Thromboembolism (VTE): Prophylaxis in Orthopedic Surgery”, Northside Hospital Grand Rounds, May 2008.
14. “Deep Venous Thrombosis: Prophylaxis, Diagnosis & Treatment”, Dept. of Surgery Grand Rounds, Wellstar Cobb Hospital, January 2006.
15. “Deep Venous Thrombosis: Prophylaxis, Diagnosis & Treatment”, Quarterly Medical Staff Meeting, Wellstar Cobb Hospital, March 2006.
16. “Vascular Assessment and Update”, When Atypical is Typical, September 10, 2005.
17. “Vascular Assessment & Strategies: Is It All Lost?”, September 2025.
18. “Endovascular Surgery: Use of the Vascular Lab and the Vascular Institute”, October 2004.
19. “Vascular Considerations”, Comprehensive Approach to Pressure Ulcer Management, April 24, 2004.
20. “OR, ER, Ortho and Other Issues”, Comprehensive Approach to Pressure Ulcer Management, April 24, 2004.
21. “Vascular Surgery in Primary Care”, WellStar Primary Care, May 2003.

22. "Why A Wound Center", Selected Issues in Wound Care, April 26, 2003.
23. "Wound Center Philosophy", The Diabetic Foot – A Challenge in Wound Care", April 2002.
24. "Management of Upper and Lower Extremity Venous Disease", 11th Annual Symposium, "Advances in Ultrasound", North Texas Ultrasound Society, August 28, 1994.
25. "Cerebrovascular Disease – Diagnosis and Management," 11th Annual Symposium, "Advances in Ultrasound", North Texas Ultrasound Society, August 28, 1994.
26. "Vascular Grafts – Why Do They Clot?" Current Topics in General Surgery, University of Texas Southwestern Medical Center, May 6, 1994.
27. "Role of Physical Examination in Detection of Abdominal Aortic Aneurysms," 33rd Annual Meeting, North Texas Chapter of the American College of Surgeons, February 18, 1994.
28. "Role of Physical Examination in Detection of Abdominal Aortic Aneurysms," 18th Annual Meeting, Southern Association for Vascular Surgery, January 27, 1994.
29. "Conduit Options," Current Topics in General Surgery, University of Texas Southwestern Medical Center, May 4, 1993.
30. "Management of the Infected Aortic Graft," Surgical Rounds Special Symposium – Abdominal Sepsis, University of Texas Southwestern Medical Center, March 20, 1993.
31. "Endovascular Obliteration of In-Situ Saphenous Vein and Arteriovenous fistula during tibial bypass," 2nd Annual Winter Meeting, Peripheral Vascular Surgery Society, Breckinridge, Colorado, January 26, 1992.
32. "Prevention of Graft Infection using Prostheses with a Rifampin/Collagen Release System," 6th Annual Meeting, Western Vascular Society, Rancho Mirage, January 16, 1991.
33. "Indications for Vascular Surgical Consultation," UCLA Medicine Residents' Conference, December 1989.
34. "Efficacy of Steroids in Suppression of Intimal Hyperplasia," 7th Annual Meeting, Southern California Vascular Surgical Society, San Diego, September 25, 1988.
35. "Efficacy of Corticosteroids in Suppression of Intimal Hyperplasia," Society for Vascular Surgery/International Society for Cardiovascular Surgery, Chicago, June 15, 1988.
36. "Skeletal Muscle Function after Ischemia and Reperfusion," Thirteenth Annual Society of University Surgeons Resident Program, San Antonio, February 10, 1988.